Some authors demonstrated that abatacept (CTLA4-Ig) preserves β-cells function in patients with a recent onset of T1D, slowing the decline of C-peptide during the 2 years of treatment by 9.6 months [95]. Here, CTLA4 is linked to type 1 diabetes mellitus.